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Cancer Therapeutic Insights

Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to
Gemcitabine Resistance in Pancreatic Cancer
Bing Song1, X. Shawn Liu2, Steven J. Rice1, Shihuan Kuang3,6, Bennett D. Elzey4,6, Stephen F. Konieczny1,6,
Timothy L. Ratliff4,6, Tony Hazbun5,6, Elena G. Chiorean7, and Xiaoqi Liu2,5

Abstract
Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all
patients eventually develop resistance to this agent. Previous studies identiﬁed Polo-like kinase 1 (Plk1) as the
mediator of gemcitabine resistance, but the molecular mechanism remains unknown. In this study, we show
that Plk1 phosphorylation of Orc2 and Hbo1 mediates the resistance to gemcitabine. We show that the level of
Plk1 expression positively correlates with gemcitabine resistance, both in pancreatic cancer cells and xenograft
tumors. Overexpression of Plk1 increases gemcitabine resistance, while inhibition of Plk1 sensitizes pancreatic
cancer cells to gemcitabine treatment. To validate our ﬁndings, we show that inhibition of Plk1 sensitizes
tumors to gemcitabine treatment in a mouse xenograft study. Mechanistically, we ﬁnd that Plk1 phosphorylation of Orc2 maintains DNA replication on gemcitabine treatment. Furthermore, Plk1 phosphorylation of
Hbo1 transcriptionally increases cFos expression and consequently elevates its target multidrug resistance 1
(MDR1), which was previously reported to confer chemotherapeutic drug resistance. Knockdown of cFos or
MDR1 sensitizes gemcitabine-resistant cells to gemcitabine treatment. Finally, pancreatic cancer cells expressing Plk1-unphosphorylatable mutants of Orc2 or Hbo1 are more sensitive to gemcitabine than cells expressing
wild-type Orc2 or Hbo1. In short, our study provides a mechanism for Plk1-mediated gemcitabine resistance,
suggesting that Plk1 is a promising target for treatment of gemcitabine-resistant pancreatic cancer. Mol Cancer
Ther; 12(1); 58–68. 2012 AACR.

Introduction
The pancreas is a unique organ that has both exocrine
and endocrine compartments. Pancreatic cancer is the
fourth leading cause of cancer-related death in the United
States, with a 5-year survival rate of less than 6%. More
than 90% of pancreatic cancers arise from the exocrine
portion of the pancreas and are pancreatic ductal adenocarcinomas. Because of a lack of early cancer-related
symptoms, patients with pancreatic cancer are often diagnosed at an advanced stage (1, 2).
Gemcitabine, a deoxycytidine analogue, is the standard
chemotherapy treatment for advanced pancreatic cancer.
Gemcitabine can directly incorporate into DNA or inhibit
ribonucleotide reductase to prevent DNA replication and,
thus, tumor cell growth (3). However, almost all patients
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have either primary or eventually gain secondary resistance
to gemcitabine treatment. The major causes for resistance
can be summarized into 3 aspects: failure of gemcitabine
uptake through hENT1 transporter, decrease of effective
drug dose by enzyme metabolism, and gain of resistance to
cellular stresses or apoptosis. Because of potential improved cytotoxicity, several combination therapies of gemcitabine plus additional agents are being tested in clinical
trials. So far, gemcitabine with erlotinib, an epidermal
growth factor receptor tyrosine kinase inhibitor, is the only
U.S. Food and Drug Administration-approved combination treatment. This regimen has a modest effect, which can
prolong median overall survival for less than 2 weeks (4).
Thus, understanding the molecular events that occur during the development of gemcitabine resistance will lead to
improvement of pancreatic cancer treatments.
Polo-like kinase 1 (Plk1) is a well-studied serine and
threonine protein kinase. It plays important roles in cell
proliferation, such as mitotic entry, centrosome maturation, kinetochore-microtubule attachment, chromosome
segregation, and cellular checkpoint adaptation (5–12).
Although evidence of Plk1 as an oncogene is scarce, it is
overexpressed in various tumors. In addition, the level
of Plk1 correlates with poor prognosis of cancer patients
(13). Inhibition of Plk1 induces mitotic arrest, followed by
cell death in cancer cells, but not in normal cells (14). A
recent study suggests that Plk1 might be a mediator for
gemcitabine resistance in pancreatic cancer. Among
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approximately 40 potential target genes, Plk1 was the only
gene that distinguished gemcitabine-sensitive versus
-resistant tumors (15). Our previous work indicates that
Plk1 phosphorylates origin recognition complex 2 (Orc2)
to promote DNA replication under replication stress such
as the one induced by gemcitabine treatment (16). We also
reported that Plk1 regulates prereplicative complex (preRC) formation through phosphorylation of histone acetyltransferase binding to the Orc1 (Hbo1; ref. 17). Therefore,
we hypothesize that Plk1-associated kinase activity
toward Orc2 and Hbo1 drives DNA replication in the
presence of gemcitabine, eventually contributing to development of gemcitabine resistance in pancreatic cancer.
To test our central hypothesis, we ﬁrst investigated the
correlation between Plk1 expression and gemcitabine
resistance with a combination of different pancreatic cell
lines, xenograft mice and pancreatic cancer patient tissues. Our data suggest that Plk1 overexpression correlates
with gemcitabine resistance in pancreatic cancer cells and
xenograft tumors. Inhibition of Plk1 activity signiﬁcantly
enhances the antitumor effect of gemcitabine in a Panc-1
xenograft model. Mechanistically, we found that Plk1
phosphorylation of Orc2 at the origin of DNA replication
is increased on gemcitabine treatment, and that cells
expressing a Plk1-unphosphorylatable mutant of Orc2
are more sensitive to gemcitabine treatment. Surprisingly,
gemcitabine treatment decreases Hbo1 at the replication
origin but recruits it to the promoter of cFos, an AP-1
transcription factor. We further show that Hbo1 phosphorylation by Plk1 upregulates the transcriptional
expression of cFos, consequently resulting in an elevation
of its target multidrug resistance 1 (MDR1). Knockdown
of cFos or MDR1 sensitizes gemcitabine-resistant cells to
gemcitabine treatment. Taken together, our ﬁndings
deﬁne an important signaling pathway of gemcitabine
resistance in pancreatic cancer, suggesting a novel strategy to treat gemcitabine-resistant pancreatic cancer.

Materials and Methods
Chemicals
BI2536 was purchased from Symansis NZ Ltd, New
Zealand. Gemcitabine (Cat. 3259) was purchased from
Tocris Bioscience (Fig. 2B and C).
Mouse xenograft model
Panc-1 cells (5 106 cells per mouse) were mixed with
an equal volume of Matrigel (Collaborative Biomedical
Products) and inoculated into the right ﬂank of athymic
nude mice (Harlan Laboratories). One week later, the
animals were randomized into treatment and control
groups of 5 mice each. BI2536 was dissolved in 0.1 N HCl,
diluted with 0.9% NaCl, and injected into the tail vein
twice weekly for 6 weeks. Gemcitabine was dissolved in
0.9% NaCl, diluted with 0.9% NaCl, and injected into the
tail vein twice weekly for 6 weeks. Tumor volumes,
estimated from the formula: V ¼ L W2/2 (V, mm3; L,
mm; W, mm), were measured on alternate days with
digital calipers.
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Statistical analysis
A standard 2-tailed unpaired Student t test was
used to calculate differences between samples. Oneway ANOVA was used to determine statistically signiﬁcant differences from the mean in the xenograft
study.
Cell culture, transfection, and RNAi
The Panc-1 and BxPC-3 cells were purchased from the
American Type Culture Collection. Cells were initially
grown and multiple aliquots were stored at 180 C for
future use as required. Cells were purchased more than 6
months ago and were not further tested or authenticated
by the authors. Panc-1 cells were cultured in Dulbecco’s
Modiﬁed Eagle Medium supplemented with 10% FBS,
100 units/mL penicillin, and 100 units/mL streptomycin
at 37 C in 5% CO2. BxPC-3 cells were cultured in
RPMI1640 medium. HPDE6 cells were cultured in keratinocyte medium (Invitrogen). Plasmid DNA was transfected with MegaTran (Origene) as described by the
manufacturer. The cFos (sc-29221) and MDR1 (sc-29395)
siRNAs were purchased from Santa Cruz Biotechnology
and transfected with Oligofectamine (Invitrogen) as
described by the manufacturer.
Western blotting
After cells were lysed in AMI lysis buffer (Active
Motif), proteins were detected by Western blotting with
antibodies against Plk1 (sc-17783; Santa Cruz Biotechnology), b-actin (A5441; Sigma), and PARP (AB3565;
Millipore).
Immunohistochemistry
After murine or human parafﬁn-embedded slides were
deparafﬁnized and rehydrated, antigens were retrieved in
antigen unmasking solution (Vector Laboratories) with a
2100-Retriever (PickCell Laboratories). Samples were
then incubated with primary antibodies against Plk1
(08544; Upstate) and Ki-67 (ab16667; Abcam) or subjected
to TUNEL assay (11684817910; Roche).
Cell viability assay
Cells were grown in 96-well plates, and viable cell
numbers were determined with the CellTiter-Glo Luminescent Cell Viability Assay kit (Promega) as described by
the manufacturer.
Combination index
IC50 and combination index of gemcitabine and BI2536
were calculated as indicated in (18). Combination index
more than 1 indicates antagonism; combination index less
than 1 indicates synergy; and combination index equal to 1
indicates an additive effect.
BrdU labeling assay
BrdU-labeling assays were conducted with a kit from
Roche (Cat.11170376001) according to the manufacturer’s
instructions.
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TUNEL assay
TUNEL assays were conducted with a kit from Roche
(Cat.11684817910) according to the manufacturer’s
instructions. Details of isolation of cells from xenograft
tumors, chromatin immunoprecipitation (ChIP), and
quantitative real-time PCR (qRT-PCR) analysis are
described in supplementary material.

Results
Plk1 is overexpressed in pancreatic tumors
To follow the expression of Plk1 protein in pancreatic
ductal adenocarcinoma, we conducted immunohistochemical (IHC) staining of Plk1 on a pancreatic tissue
microarray (n ¼ 140) that included normal pancreas,
cancer-adjacent tissue, and pancreatic ductal adenocarcinoma. We found that nearly 80% of the tumors had
positive Plk1 staining (60% with strong staining and
20% with weak staining), while only 20% of the canceradjacent tissue had positive Plk1 staining, and 80% to 90%
of normal tissues had no Plk1 staining (Fig. 1). The
difference of Plk1 protein expression between normal and
cancer tissues is statistically signiﬁcant. Taken together,
these data suggest that Plk1 is signiﬁcantly differently
expressed between normal and cancerous tissue.
Plk1 expression correlates with gemcitabine
resistance in vitro and in vivo
To investigate whether the elevated Plk1 protein
levels in pancreatic tumor samples correlates with an
active role of Plk1 in gemcitabine resistance of pancreatic cancer, we measured the IC50 values of gemcitabine
in 4 different pancreatic cell lines, HPDE6 (an immortalized human pancreatic epithelial cell line), BxPC-3
(human pancreatic cancer cell line), Panc-1 (human
pancreatic cancer cell line), and AsPC-1 (human pancreatic cancer cell line). HPDE6 and BxPC-3 had low
IC50 values, thus representing gemcitabine-sensitive
cell ines, while Panc-1 and AsPC-1 cells had high IC50
values, thus possessing the gemcitabine-resistant property (Supplementary Table S1). To compare Plk1 levels
in cell lines with different gemcitabine sensitivities and
to avoid the possibility of comparing cells at different
cell cycle stages or with different proliferation rates, we
synchronized the cells at S phase with thymidine or at M
phase with nocodazole, followed by Western blotting.
Within the same stage of the cell cycle, Panc-1 cells had
the most abundant Plk1 protein, while HPDE6 cells
had the lowest level of (Fig. 2A), positively correlating
with the gemcitabine IC50 values of these cell lines
(Supplementary Table S1).
To determine whether the sensitivity to gemcitabine is
inﬂuenced by Plk1 activity, we measured the combination
index of gemcitabine and BI2536 (an ATP competitive
inhibitor that speciﬁcally inhibits Plk1 kinase activity) as
described in the materials and methods section (Fig. 2B
and C). The IC50 value of gemcitabine for Panc-1 cells was
1284 nmol/L (Table 1). However, the IC50 of gemcitabine

60

Mol Cancer Ther; 12(1) January 2013

was reduced to 44 nmol/L when the cells were treated in
combination with 2 nmol/L BI2536. The combination
index was calculated to be 0.3 (Table 1), which is less than
1, suggesting a synergistic effect between gemcitabine and
BI2536.
Because Panc-1 cells have the highest Plk1 level and are
most resistant to gemcitabine, we treated Panc-1 cells with
gemcitabine, BI2536 alone, or gemcitabine in combination
with BI2536. We followed cell death by Western blot of
cleaved-PARP protein. PARP is a poly ADP-ribose polymerase that facilitates the survival of cells. Cleavage of
PARP disassembles cellular structure and serves as a
marker for cellular apoptosis. Gemcitabine or BI2536
alone had a minimal effect on cell death, but inhibition
of Plk1 activity by BI2536 enhanced gemcitabine-induced
cellular apoptosis (Fig. 2D). Consistent with the result
in Fig 2D, the combination of gemcitabine and BI2536
led to signiﬁcantly reduced cell survival compared with
gemcitabine or BI2536 alone (Supplementary Fig. S1A),
indicating that inhibition of Plk1 sensitizes gemcitabineresistant cells to the chemotherapy. To further expand
our observation, we also repeated this experiment in
AsPC-1 cells, which is a gemcitabine-resistant cell line,
and detected similar enhanced cellular apoptosis by inhibition of Plk1 activity using BI2536 in the presence of
gemcitabine (Supplementary Fig. S1C and D). To conﬁrm
this observation, we overexpressed Plk1 in HPDE6 cells,
which have the lowest Plk1 protein level. Plk1 overexpression induced gemcitabine resistance as shown by a
decreased cleaved-PARP protein level compared with
control samples (Fig. 2E). In conclusion, the level of Plk1
protein inﬂuences responsiveness to gemcitabine treatment in pancreatic cells.
With the aim to better assess the correlation between
Plk1 protein expression and gemcitabine sensitivity,
we examined the Plk1 protein level in xenograft tumors. Brieﬂy, animals bearing subcutaneous pancreatic
tumors derived from Panc-1 cells were treated with
40 mg/kg gemcitabine. After 8 weeks of treatment, the
tumors showed different responses to gemcitabine.
We repeated this experiment for several times, and
observed a similar trend that the Plk1 protein expression level is relatively lower in tumors with smaller
volume, indicating that these tumors are more sensitive
to gemcitabine treatment (Fig. 2F–I). Cyclin A protein
levels in these tumors are similar, suggesting that Plk1
protein expression levels were compared in tumor cells
with a similar cell-cycle distribution. Two substrates of
Plk1 that might be involved in Plk1-mediated gemcitabine resistance were also measured. Neither Orc2 nor
Hbo1 protein levels show any obvious differences
among these tumors; therefore, it is unlikely that gemcitabine resistance is more related to the protein levels
of the Orc2 and Hbo1 (Fig. 2I). More importantly, to
assess the signiﬁcance of this correlation, we quantiﬁed
the Plk1 protein levels (Fig. 2I) and measured the correlation efﬁciency between Plk1 expression signal intensity and tumor volume by Pearson product-moment
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Figure 1. Plk1 is overexpressed in pancreatic cancer tissues. A, representative images of immunohistochemical staining of a pancreatic cancer tissue
microarray with an anti-Plk1 antibody. This tissue microarray includes pancreatic adenocarcinomas, cancer adjacent tissues, and normal pancreatic
tissues. B, a representative image of Plk1 immunohistochemical staining of normal pancreatic tissue. C, a representative image of weak Plk1
immunohistochemical staining of pancreatic adenocarcinoma tissue. D, a representative image of strong Plk1 immunohistochemical staining of pancreatic
adenocarcinoma tissue. E, quantiﬁcation of Plk1 immunohistochemical staining in the pancreatic cancer tissue microarray. (The difference between
normal and cancer pancreatic tissue samples is signiﬁcant, P < 0.05).

correlation coefﬁcient analysis (Fig. 2J). The value of
Pearson product-moment correlation coefﬁcient (R) was
equal to 0.90 with P values less than 0.05, suggesting
a highly linear correlation between Plk1 protein expression and tumor volume. We also compared protein
expression level of Plk1 between control untreated
tumors and gemcitabine-treated tumors. Three untreated control tumors all showed high levels of Plk1 expression; while the gemcitabine-sensitive tumors tended
to have lower levels of Plk1, the gemcitabine-resistant

www.aacrjournals.org

tumors retained high levels of Plk1 (Fig. 2K). The
decrease of Plk1 levels can be because of individual
host–tumor interaction or the heterogeneity of cultured cancer cells, but either case supports a role of high
levels Plk1 in maintaining gemcitabine resistance.
These results are consistent with our observations in
the cell-based experiments, providing additional evidence to support a functional correlation between Plk1
protein expression and gemcitabine resistance in pancreatic cancer.
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Figure 2. Plk1 expression correlates
with gemcitabine resistance in cells
and in vivo. A, HPDE6, BxPC-3, and
Panc-1 cells were synchronized by
thymidine (24 hours) or nocodazole
(10 hours) treatment, then wholecell lysates were extracted and
analyzed by anti-Plk1 and antib-actin Western blots. B, Panc-1
cells were treated with gemcitabine
(100 nmol/L), BI2536 (1 nmol/L),
or both for 72 hours, followed
by Western blotting. C, structure
of BI2536. D, structure of
gemcitabine. E, HPDE6 cells
were infected with lentivirus to
overexpress Plk1. Twelve hours
after infection, cells were
treated with gemcitabine (50 or
200 nmol/L) for 24 hours and
harvested for Western blotting.
F, Panc-1-derived xenograft
tumors from nude mice that had
been treated with gemcitabine
(40 mg/kg) twice a week for
8 weeks. G, volumes of tumors in F.
H, weights of tumors in F. I, proteins
were extracted from the tumors as
in F and analyzed by Western blots.
J, the correlational efﬁciency
between Plk1 expression signal
intensity in I and tumor volume is
measured by Pearson productmoment correlation coefﬁcient
analysis (R, 0.90; P < 0.05). K,
proteins were extracted from
gemcitabine-treated or -untreated
Panc-1-derived xenograft tumors
and analyzed by Western blots.
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Inhibition of Plk1 sensitizes pancreatic tumors to
gemcitabine treatment in vivo
To test if elevated Plk1-associated kinase activity
in pancreatic cancer contributes to induction of gemcitabine resistance in vivo, we next examined the effects
of gemcitabine and BI2536, alone or in combination,
on subcutaneous pancreatic tumors. As indicated in
Fig. 3A, neither treatment with gemcitabine alone nor
BI2536 alone signiﬁcantly prevented tumor growth,
likely due to the relatively low concentrations of the
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drugs used in this study. In striking contrast, a combination of the same doses of gemcitabine and BI2536
strongly inhibited tumor growth, suggesting that inhibition of Plk1 sensitizes pancreatic tumors to gemcitabine treatment.
Apoptosis and cell proliferation were further examined by TUNEL and Ki-67 staining on tumor sections
prepared from these xenograft tumors by the end of
the study. As shown in Fig. 3B, the combination of
gemcitabine and BI2536 signiﬁcantly increased cell
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Table 1. The IC50 values of gemcitabine and
BI2536 in Panc-1-cells
Drugs

IC50 (nmol/L)

BI2536
Gemcitabine
Gemcitabine (in
combination with
2 nmol/L BI2536

3.68
1,284.07
44.35

Notes

Combination
index ¼ 0.3

death compared with control or monotherapy groups.
Although control tumors showed moderately faster cell
proliferation, the 4 groups of tumors did not have a
statistically signiﬁcant different rate of cell proliferation
as shown by Ki67 staining (Fig. 3C). These data suggest
inhibition of Plk1 enhances the efﬁcacy of gemcitabine
mainly by promoting cell death.
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Figure 3. Inhibition of Plk1 sensitizes xenograft tumors to gemcitabine
6
treatment. A, Panc-1 cells (5 10 ) were inoculated into ﬂanks of female
nude mice. One week after inoculation, the mice were treated with
gemcitabine (40 mg/kg), BI2536 (15 mg/kg), or a combination of both
drugs, and the relative sizes of the tumors in each group were plotted
against the number of days (P < 0.01). B, in situ TUNEL assay of the
xenograft tumors. The average percentages of TUNEL-positive cells from
multiple tumor sections were calculated to assess the degree of cell
death (P < 0.05). C, immunohistochemistry staining of Ki-67 of xenograft
tumors. The average percentages of Ki-67-positive cells from multiple
tumor sections were calculated to assess cell proliferation.

www.aacrjournals.org

Inhibition of Plk1 counteracts gemcitabine resistance
in cells
To conﬁrm that Plk1 confers gemcitabine resistance in
pancreatic cancer, we isolated tumor cells from Panc-1derived xenograft tumors with different resistance levels
to gemcitabine (Supplementary Fig. S2A–D). Fourteen
tumors were used to generate the sublines, 8 sublines
were generated. As shown in Fig. 4A, consistent with our
previous observations, the gemcitabine-sensitive tumors
(#6) had a lower level of Plk1. Interestingly, the p-Orc2
level increased 3-fold for tumor #19 compared with tumor
#6, and increased by 4-fold for tumor #21 compared with
tumor #6, which correlated with the high expression of
Plk1 (Fig. 4A). In vitro measurement of the gemcitabine
IC50 values of these tumor cells further conﬁrmed their
gemcitabine resistance (Fig. 4B). Cells derived from
tumors 19 and 21 had higher gemcitabine IC50 values in
vitro corresponding to their larger tumor sizes in vivo.
Because of these elevated Plk1 levels and higher gemcitabine IC50 values, we further treated those gemcitabineresistant tumor cells with gemcitabine in vitro, alone or in
combination with BI2536. Both gemcitabine-resistant
tumor cells became more gemcitabine sensitive in the
presence of a low dosage of BI2536 (Fig. 4C, 4D), while
the same dosage of BI2536 alone did not signiﬁcantly
affect the cell viability (Supplementary Fig. S2 E and F).
Finally, we further conﬁrmed that the gemcitabine-resistant tumor cells are more sensitive to inhibition of Plk1 on
the basis of the more rapid response of these cells to BI2536
treatment as measured by pH3 staining (Histone H3 is
speciﬁcally phosphorylated at Ser10 during mitosis,
which can serve as a mitotic marker) and FACS analysis
(Supplementary Fig. S2G and H). These analyses support
the notion that Plk1 confers the gemcitabine resistance of
pancreatic cancer.
Plk1 phosphorylation of Orc2 promotes DNA
replication in the presence of gemcitabine
Next, we dissected the mechanism for Plk1-associated
gemcitabine resistance in pancreatic cancer. Orc2 is a key
component of the pre-RC complex, which plays important
roles in initiation of DNA replication (19). We recently
reported that Plk1 phosphorylation of Orc2 promotes
DNA replication under various stress conditions (16).
Because gemcitabine-resistant pancreatic tumors have
elevated Orc2 phosphorylation, we hypothesize that Plk1
phosphorylation of Orc2 is a driving force for cell proliferation in the presence of gemcitabine in pancreatic
cancer.
We ﬁrst asked whether Plk1-mediated Orc2 phosphorylation is enhanced at the replication origin by the DNA
replication stress induced by gemcitabine. Toward this end,
we conducted ChIP experiments with antibodies against
Orc2 and p-Orc2, and examined the well-deﬁned Orc2associated DNA replication origin (MCM4). As shown
in Fig. 5A, we were able to detect the signal by Orc2
antibody on the MCM4 origin ( 500 genomic units) and
the signal by phospho-Orc2 antibody ( 200 genomic units)
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in control cells without gemcitabine treatment. After gemcitabine treatment, the signal by Orc2 antibody remained
about the same, but the signal by the p-Orc2 antibody
increased to approximately 450 genomic units, an approximately 2-fold increase compared with untreated cells (Fig.
5A). This observation supports our hypothesis that Plk1mediated phosphorylation of Orc2 at the replication origin
is elevated in response to gemcitabine treatment.
To further evaluate the signiﬁcance of this phosphorylation event in resistance to gemcitabine in pancreatic
cancer, Panc-1 cells expressing Orc2-WT or Orc2-A (Plk1
unphosphorylatable mutant, S188A) were treated with
gemcitabine and subjected to BrdU labeling assays (Supplementary Fig. S3A). Without gemcitabine treatment,
Orc2-WT and Orc2-A cells displayed similar incorporation of BrdU. However, Orc2-A-expressing cells
showed reduced DNA replication compared with Orc2WT cells upon gemcitabine treatment (Fig. 5B). This result
suggests that Panc-1 cells expressing the Orc2-A mutant
are more sensitive to gemcitabine treatment, indicating
that Plk1 phosphorylation of Orc2 maintains DNA replication capacity in the presence of gemcitabine. Treating
Panc-1 cells with BI2536 also decreases p-Orc2 level (Supplementary Fig. S1B). To further conﬁrm this notion, we
examined cell death in these two populations upon gemcitabine treatment. Cells expressing the Orc2-A mutant
showed increased cell death compared with cells expressing Orc2-WT, suggesting that Plk1 phosphorylation of
Orc2 is, indeed, one mechanism for increased gemcitabine
resistance in pancreatic cancer (Fig. 5C).
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Figure 4. Inhibition of Plk1
counteracts the gemcitabine
resistance in cells derived from
gemcitabine-resistant tumors.
A, Panc-1-derived xenograft
tumors were treated as in Fig. 3A
to generate tumors with different
sensitivities to gemcitabine. Part of
each tumor sample was subjected
to protein extraction for Western
blots. B, cells isolated from the
tumors as in A were grown in
96-well plates and cell viability
was assessed. C and D, isolated
gemcitabine-resistant cells (#19
and #20) were grown in 96-well
plates, treated with gemcitabine
alone or in combination with
BI2536, and cell viability was
assessed (P < 0.05).
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Plk1 phosphorylation of Hbo1 increases cFos,
consequently elevating its target, MDR1
Hbo1, the enzyme responsible for histone H4 acetylation, is a core subunit of a protein complex comprised
of JADE1/2/3 paralogs, hEaf6 and ING5. This complex
interacts with the Mcm helicase and is essential for
DNA replication to occur during S phase (20). Recently,
it was reported that Hbo1 is recruited to the promoter
of AP-1 and serves as a coactivator to increase AP-1
transcription in response to environmental stress (21).
More importantly, the expression level of Hbo1 is
high in various human carcinomas (22). Previous studies in our laboratory showed that Plk1 phosphorylation
of Hbo1 positively regulates its acetylation activity
to promote DNA replication (17). Given these facts,
we next asked whether Plk1 phosphorylation of Hbo1
also contributes to gemcitabine resistance in pancreatic
cancer.
To test this hypothesis, we ﬁrst conducted BrdU-labeling assays with cells expressing Hbo1-WT or Hbo1-A
mutant (Plk1 unphosphorylatable mutant, S57A; Supplementary Fig. S3B). As shown in Supplementary Fig. S3C,
cells expressing Hbo1-A are more sensitive to gemcitabine
treatment as compared with cells expressing Hbo1-WT.
As a result of this sensitivity, cells expressing Hbo1-A
showed increased cell death as indicated by an increased
cleaved-PARP protein level after gemcitabine treatment
(Supplementary Fig. S3D). These data suggest that Plk1
phosphorylation of Hbo1 also plays a role in gemcitabine
resistance of pancreatic cancer.
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A
Figure 5. Plk1 phosphorylation of
Orc2 promotes DNA replication in
the presence of gemcitabine. A,
Panc-1 cells were treated with
gemcitabine (50 mmol/L) for 12
hours and then subjected to ChIP
analysis. The qRT-PCR was carried
out with DNA that was extracted
from chromatin precipitated with
antibodies against Orc2 or p-Orc2.
The MCM4 locus represents an
established replication origin (29).
In6 is the region 6-kb upstream of
the MCM4 locus, and Ex9 is the
region 5-kb downstream of the
MCM4 locus. B, Panc-1 cells were
transfected with Orc2-WT
or Orc2-A constructs and
synchronized by a double
thymidine block (DTB, 16-hour
thymidine block, 8 hours of release,
followed by a second thymidine
block for 16 hours) protocol. After
release from the second thymidine
block, cells were treated with
gemcitabine (50 or 200 nmol/L) for
24 hours, followed by BrdU labeling
assay. C, whole-cell lysates from
Panc-1 cells treated as in B were
subjected to Western blots.
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To dissect the mechanism of this observation, we ﬁrst
examined the occupancy of endogenous Hbo1 at the
replication origin upon gemcitabine treatment by ChIP
analysis. To our surprise, Hbo1 was signiﬁcantly
decreased from the replication origin after gemcitabine
treatment (Supplementary Fig. S3E). Instead, we observed
that Hbo1 accumulated at the promoter of cFos (Fig. 6A),
an AP-1 transcription factor. This observation is consistent
with the previous report that Hbo1 is recruited at the cFos
promoter site to serve as a transcriptional coactivator
upon stress (21). Therefore, it is possible that Hbo1 at the
cFos promoter activates cFos gene transcription. As the
induction of cFos by therapeutic drug treatment is
involved in the acquisition of drug resistance (23–25), we
then examined whether cFos transcription is induced by
gemcitabine treatment. As shown in Fig. 6B, the expression level of cFos was increased by 2.5-fold after 1-hour
gemcitabine treatment. Further, overexpression of Hbo1WT, but not Hbo1-A, signiﬁcantly ampliﬁed the induction
of cFos (20-fold) on gemcitabine treatment (Fig. 6C),
suggesting phosphorylation of Hbo1 contributes to the
induction of cFos by gemcitabine treatment.
To test whether the elevated cFos contributes to gemcitabine resistance in pancreatic cancer, we next examined
its transcriptional target, MDR1, as MDR1 has been
reported to mediate drug resistance by exporting drugs
out of cells (24, 26, 27). Consistent with the results in Fig.
6C, we observed that overexpression of Hbo1-WT, but not
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Hbo1-A, also ampliﬁed the induction of MDR1 (3-fold)
upon gemcitabine treatment (Fig. 6D). Moreover, the
expression levels of cFos and MDR1 were higher in
gemcitabine-resistant cells than in gemcitabine-sensitive
cells (Fig. 6E and F), suggesting a possible role of the cFosMDR1 pathway in gemcitabine resistance. To conﬁrm the
contribution of Plk1 phosphorylation of Hbo1 on the
elevation of cFos and MDR1, we treated the gemcitabine-resistant cells with BI2536 and examined the expression of cFos and MDR1. As shown in Fig. 6G and H,
inhibition of Plk1 decreased cFos expression by 50% and
MDR1 expression by 40%, conﬁrming the role of Plk1
phosphorylation of Hbo1 on the elevation of cFos and
MDR1 levels. Finally, to test whether elevated expressions
of cFos and MDR1 confer gemcitabine resistance, we
employed RNAi to knock down their expression in gemcitabine-resistant cells (Supplementary Fig. S4), and
found that the IC50 of gemcitabine was reduced from
171.2 to 14.9 mmol/L after cFos RNAi transfection and to
1.0 mmol/L after MDR1 RNAi transfection (Fig. 6I). These
data suggest that elevated cFos and MDR1 maintain the
gemcitabine resistance in pancreatic cancer.
Finally, to test the contribution of these two phosphorylation events to gemcitabine resistance, Panc-1 cells
were synchronized, transfected, and treated with or
without gemcitabine. As shown in Fig. 6J, Panc-1 cells
expressing Hbo1-A alone showed less cleaved-PARP
protein level than cells expressing both Hbo1-A and
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Figure 6. Plk1 phosphorylation of Hbo1 increases cFos expression and consequently elevates its target, MDR1. A, Panc-1 cells were treated with gemcitabine
(50 mmol/L) for 12 hours and then subjected to ChIP analysis with anti-Hbo1 antibody. qRT-PCR was carried out with DNA extracted from precipitated
chromatin to examine the association of Hbo1 on the promoters of cFos and Sat2 (P < 0.05). Hbo1 localization on the promoter of Sat2 is not induced by
stress and, thus, serves as a negative control for this experiment (#21). B, Panc-1 cells were treated with gemcitabine and harvested at different times
after treatment. The mRNA level of cFos from each sample was quantiﬁed by qRT-PCR and normalized to a mock control. C and D, Panc-1 cells were
transfected with Flag-Hbo1-WT, Flag-Hbo1-S57A, or Flag vector alone, treated with gemcitabine, and harvested at different times after treatment. The
mRNA level of cFos (C) and MDR1 (D) for each sample was examined by qRT-PCR (P < 0.05). The mRNA levels of cFos (E) and MDR1 (F) in the
gemcitabine-sensitive Panc-1 cell line (#6) and gemcitabine-resistant Panc-1 cell lines (#19 and #21) were examined by qRT-PCR. G and H, after
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by qRT-PCR (P < 0.05). I, gemcitabine-resistant Panc-1 cells (#19) were transfected with cFos or MDR1 siRNA for 24 hours and the IC50 values of
gemcitabine were determined. J, Panc-1 cells were synchronized by double thymidine block protocol, then transfected with Flag-Hbo1-A, GFP-Orc2-A,
or both, then treated with or without gemcitabine (50 nmol/L) for 24 hours, and subjected to Western blot analysis.

Orc2-A mutants in response to gemcitabine treatment.
Cells expressing Orc2-A alone has a similar cleavedPARP protein expression level as cells expressing both
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mutants. This result suggests that Plk1 phosphorylation
of Orc2 might be a dominant mechanism for Plk1-mediated gemcitabine resistance.
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Discussion
Gemcitabine is the current standard chemotherapy for
pancreatic cancer, a deadly disease. However, only 30% of
patients beneﬁt from this agent, and among those, almost
all will become resistant, usually within 3 to 4 months. In
this study, we have investigated the putative mechanisms
of gemcitabine resistance in pancreatic tumors. We found
that Plk1 phosphorylation of Orc2 and Hbo1 mediates
gemcitabine resistance and that inhibition of Plk1 sensitizes pancreatic tumor cells to gemcitabine treatment in
vitro and in vivo. Plk1 blockade may represent a novel
avenue for treatment of gemcitabine-resistant pancreatic
cancer.
Plk1 is a well-established regulator of many mitosisrelated events. However, our recent work suggests that
Plk1 might also have functions in interphase events, such
as DNA replication. For example, we showed the involvement of Plk1 in promotion of DNA synthesis by phosphorylation of Orc2 under replication stress. Moreover,
elevated levels of Plk1 and phoshpho-Orc2 in pancreatic
tumors are correlated with gemcitabine resistance (Figs. 2
and 3). Increased phosphorylation of Orc2 at the replication origin on gemcitabine treatment maintains DNA
replication for cell survival (Fig. 5A and B). As a consequence, pancreatic cancer cells expressing the Plk1unphosphorylatable mutant of Orc2 became more sensitive to gemcitabine treatment (Fig. 5C), suggesting that
Plk1-mediated phosphorylation of Orc2 is one mechanism that contributes to gemcitabine resistance of pancreatic cancer.
We acknowledge that Plk1 likely regulates cellular
responses to gemcitabine treatment via multiple mechanisms. We also reported previously that Hbo1 is phosphorylated by Plk1 to regulate DNA replication (17). To our
surprise, we observed a decrease of Hbo1 at the replication origin upon gemcitabine treatment (Supplementary
Fig. S3E). Instead, Hbo1 accumulated at the promoter
region of cFos, an AP-1 transcription factor (Fig. 6A),
which is consistent with the recent report of Hbo1 recruitment to the AP-1 promoter under environmental stress
and the overall role of Hbo1 in regulating the p53 pathway
(21, 28). These observations suggest that Hbo1 might
contribute to gemcitabine resistance independent of its
role in DNA replication. To support this notion, we found
that cFos and its target MDR1 were signiﬁcantly induced
by gemcitabine treatment in a manner dependent on Plk1
phosphorylation of Hbo1 (Fig. 6B–D). The elevation of
cFos transcription is likely due to the accumulation of
Hbo1 at the cFos promoter on gemcitabine treatment (Fig.
6A). In the gemcitabine-resistant Panc-1 cells that we
isolated from xenograft tumors, both cFos and MDR1
expression were elevated (Fig. 6E, F). Signiﬁcantly, knockdown of cFos or MDR1 sensitizes these gemcitabineresistant cells to gemcitabine treatment. Additional genes
in the p53 pathway that are regulated by Hbo1 may also
have a role in gemcitabine resistance, but our data support
one mechanism of Hbo1-mediated resistance in which
overexpressed Plk1 in pancreatic tumors phosphorylates
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Hbo1 to elevate cFos and its target MDR1, eventually
contributing to gemcitabine resistance.
Combining these results with the data of Orc2 described
above, we propose a model that Plk1 phosphorylates Orc2
and Hbo1 to mediate gemcitabine resistance in pancreatic
cancer. As shown in Fig. 3, inhibition of Plk1 kinase
activity signiﬁcantly enhanced gemcitabine sensitivity in
pancreatic cancer. Gemcitabine treatment alone did not
signiﬁcantly increase cell death or block cell proliferation
in the Panc-1 cell-based xenograft study, mirroring gemcitabine resistance found in the clinical setting. However,
inhibition of Plk1 in combination with gemcitabine signiﬁcantly increased cell death and prevented tumor
growth, indicating that Plk1 activity is critical for the
development of resistance to gemcitabine. Overexpression of Plk1 in HPDE6 cells, which are sensitive to gemcitabine treatment (Supplementary Table S1), induced
resistance of HPDE6 cells to gemcitabine (Fig. 2E). This
result suggests a potential role of Plk1 in secondary
resistance to gemcitabine. Further, we showed that
tumors maintaining high Plk1 levels on gemcitabine treatment were resistant to gemcitabine, and that tumors with
decreased Plk1 levels on gemcitabine treatment were
sensitive to gemcitabine (Fig. 2K), indicating that the
response of Plk1 level on gemcitabine treatment can be
used to predict the efﬁcacy of gemcitabine in the treatment
of pancreatic cancer. By examining a potential mechanism
of gemcitabine resistance of pancreatic cancer, our study
provides a novel rationale for molecularly targeting Plk1
in the treatment of this deadly disease.
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